Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment.
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CATChEz
- Sponsors Novartis
- 10 Feb 2018 Results assessing safety, efficacy and pharmacodynamics presented at the 2018 Genitourinary Cancers Symposium
- 04 Oct 2017 Last checked against ClinicalTrials.gov record.
- 26 Sep 2017 Status changed from active, no longer recruiting to discontinued.